Here's Why Johnson & Johnson Is Still in the Coronavirus Vaccine Race

Because three pharma and biotech companies have reported glowing results from their coronavirus vaccine candidates' trials over the last month, it might seem like the race is over. Even if other companies manage to cross the finish line, their tardiness would mean that they'd only be able to enjoy the scraps left over by the victors, right?

Not if Johnson & Johnson (NYSE: JNJ) has anything to say about it. Despite dismissals from skeptical investors who associate it with baby powder and tear-free shampoo rather than cutting-edge medicines, there's a solid chance that its candidate will make billions. Don't let the delay in getting J&J's results fool you: Its coronavirus vaccine will probably have several edges over the competition.

Image source: Getty Images.

Source Fool.com